I know everyone is optimistic about the future of neu, including me. But recently, I have done some more in-depth research on the past of neu. It seems that neu has failed in tbi and Glypromate has also failed. So what is the possibility that nnz-2591 can replicate the positive results in phase 3 clinical trials? Since it is the jewel in the crown, why didn't they develop nnz2591 first, but first developed Trofinetide？
I know everyone is optimistic about the future of neu, including...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.19 |
Change
0.560(3.37%) |
Mkt cap ! $2.167B | |||
| Open | High | Low | Value | Volume |
| $16.80 | $17.34 | $16.63 | $4.089M | 240.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 604 | $17.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.19 | 1 | 1 |
View Market Depth
| Last trade - 13.07pm 31/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |